# MAP2K7

Source: https://onco.cc/targets/map2k7/  
OnCo record `map2k7` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MAP2K7 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.

## Summary

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3.

CIViC holds 4 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib, Tamoxifen and Fulvestrant. IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Stomach Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: mitogen-activated protein kinase kinase 7; Dual specificity mitogen-activated protein kinase kinase 7; MKK7; Jnkk2; SAPKK4; PRKMK7
- Tags: cancer-genes-wave
- Symbol: MAP2K7
- Class: kinase
- Biology: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Location: Nucleus; Cytoplasm (UniProt). Locus 19p13.2 (HGNC).
- Where found: Lung cancer: CIViC evidence names this disease; Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD); HR-positive / HER2-negative breast cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:6847: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6847
- UniProt O14733: https://www.uniprot.org/uniprotkb/O14733/entry
- NCBI Gene 5609: https://www.ncbi.nlm.nih.gov/gene/5609
- Ensembl ENSG00000076984: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000076984

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)

---
JSON: https://onco.cc/api/v1/entities/map2k7.json